Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy, safety, and tolerability of
levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major
depressive disorder (MDD)